McDermott Advises Hookipa on Collaboration and License Agreement with Gilead
Frankfurt am Main (13 June, 2018)– McDermott Will & Emery has advised Hookipa Biotech AG, a Vienna based clinical-stage biotech company on entering into a research collaboration and license agreement with Gilead Sciences, Inc, the research-based biopharmaceutical company.
Under the terms of the agreement, Hookipa grants Gilead exclusive rights to Hookipa’s TheraT® and Vaxwave® arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and human immunodeficiency virus (HIV).
Gilead will provide an upfront payment of $10 million and fund all research and development activities. Additionally, Hookipa will be eligible to receive milestone payments based upon achievement of specified development, regulatory, and commercial milestones up to a total of more than $400 million as well as tiered royalties on net sales.
The McDermott team was led by Dr. Rüdiger Herrmann, working alongside fellow partner Jochen Eimer and Dr. Monika Richter, counsel.
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.